Lurbinectedin for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Zepzelca
Company
Jazz Pharmaceuticals, Inc.
Medicine type
Chemical medicine
Therapeutic area
Oncology
Indications recorded in the public source
US prescribing information: with atezolizumab or atezolizumab/hyaluronidase-tqjs, as maintenance treatment for adults with extensive-stage small cell lung cancer that has not progressed after first-line induction using the corresponding atezolizumab product, carboplatin and etoposide. The September 2026 label removes the prior accelerated-approval metastatic SCLC indication. This is US labeling, not confirmation of Chinese indications.
Indication source and scope
Revised 09/2026; updated 2026-09-30. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions